These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29471604)

  • 1. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?].
    Kim YS
    Korean J Gastroenterol; 2018 Feb; 71(2):74-80. PubMed ID: 29471604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies in the management of inflammatory bowel disease.
    Rutgeerts P; Baert F
    Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease: current therapeutic options.
    Domènech E
    Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic inflammatory bowel diseases: drug therapy standards and trends].
    Schölmerich J; Stange EF
    Internist (Berl); 2001 Apr; 42(4):533-8, 540-3. PubMed ID: 11326736
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R; Denis MA; Dewit O
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 12. [Conservative therapy of inflammatory bowel diseases].
    Nagy F
    Orv Hetil; 2002 Dec; 143(50):2763-8. PubMed ID: 12583315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of steroid-resistant inflammatory bowel disease.
    Manz M; Vavricka SR; Wanner R; Lakatos PL; Rogler G; Frei P; Safroneeva E; Schoepfer AM
    Digestion; 2012; 86 Suppl 1():11-5. PubMed ID: 23051721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing challenges of inflammatory bowel disease in a Turkish cohort (2006-2016).
    Yuksel I; Kilincalp S; Coşkun Y; Akinci H; Karaahmet F; Hamamci M
    Acta Gastroenterol Belg; 2018; 81(3):373-380. PubMed ID: 30350524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacologic therapy of Crohn's disease and ulcerative colitis].
    Banai J
    Orv Hetil; 2000 May; 141(22):1171-7. PubMed ID: 10853345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmacotherapy for inflammatory bowel disease.
    McKaig BC; Stack WA
    Expert Opin Pharmacother; 1999 Nov; 1(1):3-14. PubMed ID: 11249561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.